| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K34222889 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0002 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0003 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0003 |
| mRNA | CP724714 | GDSC1000 | pan-cancer | AAC | -0.13 | 0.0003 |
| mRNA | BRD-K66453893 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0003 |
| mRNA | MLN4924 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0003 |
| mRNA | alvocidib | CTRPv2 | pan-cancer | AAC | -0.19 | 0.0004 |
| mRNA | KX2-391 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0004 |
| mRNA | Bexarotene | GDSC1000 | pan-cancer | AAC | 0.14 | 0.0004 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0004 |